In patients with t(8;21) AML, the presence of minimal residual disease (MRD), measured by RUNX1-RUNX1T1 transcript levels, is now established as a powerful marker to predict relapse and to direct clinical interventions for patients receiving chemotherapy or transplantation [4–6, 10, 12–16]. Here, RUNX1 is linked to acute myeloid leukemia.